jueves, 30 de mayo de 2019

Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients. - PubMed - NCBI

Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients. - PubMed - NCBI



 2017;245:599-603.

Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients.

Abstract

Infusion-related reactions (IRRs) are typical adverse events for breast cancer patients. Detecting IRRs and visualizing their occurance associated with the drug treatment would potentially assist clinicians to improve patient safety and help researchers model IRRs and analyze their risk factors. We developed and evaluated a phenotyping algorithm to detect IRRs for breast cancer patients. We also designed a visualization prototype to render IRR patients' medications, lab tests and vital signs over time. By comparing with the 42 randomly selected doses that are manually labeled by a domain expert, the sensitivity, positive predictive value, specificity, and negative predictive value of the algorithms are 69%, 60%, 79%, and 85%, respectively. Using the algorithm, an incidence of 6.4% of patients and 1.8% of doses for docetaxel, 8.7% and 3.2% for doxorubicin, 10.4% and 1.2% for paclitaxel, 16.1% and 1.1% for trastuzumab were identified retrospectively. The incidences estimated are consistent with related studies.

KEYWORDS:

Algorithms; Patient Safety; Phenotype

PMID:
 
29295166
 
PMCID:
 
PMC5760174

[Indexed for MEDLINE] 
Free PMC Article

No hay comentarios: